Immunohistochemical analysis of cyclooxygenase-2 and brain fatty acid binding protein expression in grades I-II meningiomas: Correlation with tumor grade and clinical outcome after radiotherapy

Neuropathology

Volumn 34, Issue 5, 2014, Pages 446-454

  Kang, Hyun Cheol ^a,c   Kim, Il Han ^a,b   Park, Charn Il ^a   Park, Sung Hye ^a  

^a Seoul National University College of Medicine   (South Korea)

^b Seoul National University   (South Korea)

^c Dongnam Institute of Radiological and Medical Science   (South Korea)

Author keywords

Brain fatty acid binding protein; Cyclooxygenase 2; Immunohistochemistry; Meningioma; Radiotherapy

Indexed keywords

BIOLOGICAL MARKER; CYCLOOXYGENASE 2; FATTY ACID BINDING PROTEIN;

ADULT; DISEASE COURSE; ENZYMOLOGY; FEMALE; HUMAN; IMMUNOHISTOCHEMISTRY; MALE; MENINGEAL NEOPLASMS; MENINGIOMA; METABOLISM; MIDDLE AGED; SURVIVAL; TREATMENT OUTCOME;

ADULT; BIOLOGICAL MARKERS; CYCLOOXYGENASE 2; DISEASE PROGRESSION; FATTY ACID-BINDING PROTEINS; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MENINGEAL NEOPLASMS; MENINGIOMA; MIDDLE AGED; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 84907879384     PISSN: 09196544     EISSN: 14401789     Source Type: Journal    
DOI: 10.1111/neup.12128     Document Type: Article

References (41)

1. Claus EB, Bondy ML, Schildkraut JM, Wiemels JL, Wrensch M, Black PM. Epidemiology of intracranial meningioma. Neurosurgery 2005; 57: 1088-1095; discussion 88-95.
2. Kuratsu J, Kochi M, Ushio Y. Incidence and clinical features of asymptomatic meningiomas. J Neurosurg 2000; 92: 766-770.
3. Mirimanoff RO, Dosoretz DE, Linggood RM, Ojemann RG, Martuza RL. Meningioma: analysis of recurrence and progression following neurosurgical resection. J Neurosurg 1985; 62: 18-24.
4. Rogers L, Mehta M. Role of radiation therapy in treating intracranial meningiomas. Neurosurg Focus 2007; 23: E4.
5. Pairet M, Engelhardt G. Distinct isoforms (COX-1 and COX-2) of cyclooxygenase: possible physiological and therapeutic implications. Fundam Clin Pharmacol 1996; 10: 1-17.
6. Ragel BT, Jensen RL, Gillespie DL, Prescott SM, Couldwell WT. Ubiquitous expression of cyclooxygenase-2 in meningiomas and decrease in cell growth following in vitro treatment with the inhibitor celecoxib: potential therapeutic application. J Neurosurg 2005; 103: 508-517.
7. Lin CC, Kenyon L, Hyslop T etal. Cyclooxygenase-2 (COX-2) expression in human meningioma as a function of tumor grade. Am J Clin Oncol 2003; 26: S98-102.
8. Panagopoulos AT, Lancellotti CL, Veiga JC, de Aguiar PH, Colquhoun A. Expression of cell adhesion proteins and proteins related to angiogenesis and fatty acid metabolism in benign, atypical, and anaplastic meningiomas. J Neurooncol 2008; 89: 73-87.
9. Louis DN, Ohgaki H, Wiestler OD etal. The 2007 WHO classification of tumours of the central nervous system. Acta Neuropathol (Berl) 2007; 114: 97-109.
10. Korshunov A, Shishkina L, Golanov A. Immunohistochemical analysis of p16INK4a, p14ARF, p18INK4c, p21CIP1, p27KIP1 and p73 expression in 271 meningiomas correlation with tumor grade and clinical outcome. Int J Cancer 2003; 104: 728-734.
11. Perry A, Stafford SL, Scheithauer BW, Suman VJ, Lohse CM. The prognostic significance of MIB-1, p53, and DNA flow cytometry in completely resected primary meningiomas. Cancer 1998; 82: 2262-2269.
12. Roser F, Samii M, Ostertag H, Bellinzona M. The Ki-67 proliferation antigen in meningiomas. Experience in 600 cases. Acta Neurochir (Wien) 2004; 146: 37-44; discussion 44.
13. Kim YJ, Ketter R, Steudel WI, Feiden W. Prognostic significance of the mitotic index using the mitosis marker anti-phosphohistone H3 in meningiomas. Am J Clin Pathol 2007; 128: 118-125.
14. Loussouarn D, Brunon J, Avet-Loiseau H, Campone M, Mosnier JF. Prognostic value of HER2 expression in meningiomas: an immunohistochemical and fluorescence in situ hybridization study. Hum Pathol 2006; 37: 415-421.
15. Roser F, Nakamura M, Bellinzona M, Rosahl SK, Ostertag H, Samii M. The prognostic value of progesterone receptor status in meningiomas. J Clin Pathol 2004; 57: 1033-1037.
16. Kato Y, Nishihara H, Mohri H etal. Clinicopathological evaluation of cyclooxygenase-2 expression in meningioma: immunohistochemical analysis of 76 cases of low and high-grade meningioma. Brain Tumor Pathol 2014; 31: 23-30.
17. Jackson JR, Seed MP, Kircher CH, Willoughby DA, Winkler JD. The codependence of angiogenesis and chronic inflammation. FASEB J 1997; 11: 457-465.
18. Eberhart CE, Coffey RJ, Radhika A, Giardiello FM, Ferrenbach S, DuBois RN. Up-regulation of cyclooxygenase 2 gene expression in human colorectal adenomas and adenocarcinomas. Gastroenterology 1994; 107: 1183-1188.
19. Gupta S, Srivastava M, Ahmad N, Bostwick DG, Mukhtar H. Over-expression of cyclooxygenase-2 in human prostate adenocarcinoma. Prostate 2000; 42: 73-78.
20. Ristimaki A, Honkanen N, Jankala H, Sipponen P, Harkonen M. Expression of cyclooxygenase-2 in human gastric carcinoma. Cancer Res 1997; 57: 1276-1280.
21. Prescott SM. Is cyclooxygenase-2 the alpha and the omega in cancer? J Clin Invest 2000; 105: 1511-1513.
22. Umar A, Viner JL, Anderson WF, Hawk ET. Development of COX inhibitors in cancer prevention and therapy. Am J Clin Oncol 2003; 26: S48-S57.
23. Tsujii M, DuBois RN. Alterations in cellular adhesion and apoptosis in epithelial cells overexpressing prostaglandin endoperoxide synthase 2. Cell 1995; 83: 493-501.
24. Masferrer JL, Leahy KM, Koki AT etal. Antiangiogenic and antitumor activities of cyclooxygenase-2 inhibitors. Cancer Res 2000; 60: 1306-1311.
25. Hinz B, Brune K. Cyclooxygenase-2 - 10 years later. J Pharmacol Exp Ther 2002; 300: 367-375.
26. Ruiz J, Martinez A, Hernandez S etal. Clinicopathological variables, immunophenotype, chromosome 1p36 loss and tumour recurrence of 247 meningiomas grade I and II. Histol Histopathol 2010; 25: 341-349.
27. Kim HJ, Wu HG, Park IA, Ha SW. High cyclooxygenase-2 expression is related with distant metastasis in cervical cancer treated with radiotherapy. Int J Radiat Oncol Biol Phys 2003; 55: 16-20.
28. Khor LY, Bae K, Pollack A etal. COX-2 expression predicts prostate-cancer outcome: analysis of data from the RTOG 92-02 trial. Lancet Oncol 2007; 8: 912-920.
29. Formenti SC, Volm M, Skinner KA etal. Preoperative twice-weekly paclitaxel with concurrent radiation therapy followed by surgery and postoperative doxorubicin-based chemotherapy in locally advanced breast cancer: a phase I/II trial. J Clin Oncol 2003; 21: 864-870.
30. Huang WZ, Fu JH, Wang DK etal. Overexpression of cyclooxygenase-2 is associated with chemoradiotherapy resistance and prognosis in esophageal squamous cell carcinoma patients. Dis Esophagus 2008; 21: 679-684.
31. Pfister C, Ritz R, Pfrommer H, Bornemann A, Tatagiba MS, Roser F. Are there attacking points in the eicosanoid cascade for chemotherapeutic options in benign meningiomas? Neurosurg Focus 2007; 23: E8.
32. Han C, Wu T. Cyclooxygenase-2-derived prostaglandin E2 promotes human cholangiocarcinoma cell growth and invasion through EP1 receptor-mediated activation of the epidermal growth factor receptor and Akt. J Biol Chem 2005; 280: 24053-24063.
33. Wang D, Mann JR, DuBois RN. WNT and cyclooxygenase-2 cross-talk accelerates adenoma growth. Cell Cycle 2004; 3: 1512-1515.
34. Tuynman JB, Vermeulen L, Boon EM etal. Cyclooxygenase-2 inhibition inhibits c-Met kinase activity and Wnt activity in colon cancer. Cancer Res 2008; 68: 1213-1220.
35. Ragel BT, Jensen RL, Gillespie DL, Prescott SM, Couldwell WT. Celecoxib inhibits meningioma tumor growth in a mouse xenograft model. Cancer 2007; 109: 588-597.
36. Friedrich S, Schwabe K, Grote M, Krauss JK, Nakamura M. Effect of systemic celecoxib on human meningioma after intracranial transplantation into nude mice. Acta Neurochir (Wien) 2013; 155: 173-182.
37. Yao M, Kargman S, Lam EC etal. Inhibition of cyclooxygenase-2 by rofecoxib attenuates the growth and metastatic potential of colorectal carcinoma in mice. Cancer Res 2003; 63: 586-592.
38. Pyo H, Choy H, Amorino GP etal. A selective cyclooxygenase-2 inhibitor, NS-398, enhances the effect of radiation in vitro and in vivo preferentially on the cells that express cyclooxygenase-2. Clin Cancer Res 2001; 7: 2998-3005.
39. Czembirek C, Eder-Czembirek C, Erovic BM etal. The cyclooxygenase-2 inhibitor nimesulide, a nonsteroidal analgesic, decreases the effect of radiation therapy in head-and-neck cancer cells. Strahlenther Onkol 2009; 185: 310-317.
40. Lamszus K. Meningioma pathology, genetics, and biology. J Neuropathol Exp Neurol 2004; 63: 275-286.
41. Pasquier D, Bijmolt S, Veninga T etal. Atypical and malignant meningioma: outcome and prognostic factors in 119 irradiated patients. A multicenter, retrospective study of the Rare Cancer Network. Int J Radiat Oncol Biol Phys 2008; 71: 1388-1393.